InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,099.96
(
1.02%
)
US TECH 100
17,244.80
(
1.57%
)
Dow Jones
38,239.66
(
0.40%
)
Brent Oil
88.17
(
0.00%
)
Bitcoin
62,958.94
(
-1.22%
)
Post# of 363
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

scotty12

Send PM Follow Ignore
Followers 0
Posts 31
Boards Moderated 0
Alias Born 06/12/2010

scotty12

Re: None

Monday, 10/14/2013 3:13:38 AM

Monday, October 14, 2013 3:13:38 AM

Post# of 363
Expedition 3 trial, paid for by Eli Lilly, hopes to gain approval before being released...read somewhere that the Alzheimer's drug and pharmaceutical industry will demand somewhere in the neighborhood of 5 billion a year...this explains why the big boys (Eli Lilly, Pfizer and Novartis) are shoring up this Solanezamub product for the market, perfecting the outcome effect wished...and gaining FDA approval in the process.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up